Researchers from the United States revealed that the reception of a certain group of antidepressants – selective inhibitors of serotonin reverse seizure (SSRS) – significantly reduces the risk of death at coronavirus infection. The article of scientists is published in Jama Network Open.
Specialists from California and Stanford Universities analyzed the anonymized data of electronic medical maps 500 thousand patients in the United States. In 83.5 thousand of them, from January to September 2020, COVID-19 was found. SSRs were prescribed 3.4 thousand people from this number.
researchers compared the outcomes of coronavirus infection in those who took such drugs with COVID-19 patients in the control group, which were selected in accordance with age, floor, nationality and the presence of concomitant diseases. It turned out that the risk of die from the received fluoxetine was 28 percent less than in the control group. Those who accepted Fluoksetin or Fluvoxamine are another SIRES – this risk was less than 26 percent. In general, the reception of any SSRs was associated with a decrease in the risk of death at a coronavirus infection for eight percent.
“Data of electronic medical records allow us to quickly evaluate the existing drugs that can be recharged to treat COVID-19 and other diseases,” notes one of the authors of the work, the University of California Researcher in San Francisco Tomiko Oskotski. At the same time, the researchers emphasize in order to speak with confidence about the benefits of using this group of antidepressants at COVID-19, large-scale randomized clinical studies are needed.